Literature DB >> 21663509

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.

Grzegorz W Basak1, Gabor Mikala, Zdenek Koristek, Ozren Jaksic, Sandra Basic-Kinda, Andrea Cegledi, Marienn Reti, Tamas Masszi, Jiri Mayer, Sebastian Giebel, Kai Hübel, Boris Labar, Wieslaw Wiktor-Jedrzejczak.   

Abstract

Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 × 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 × 10(6) CD34+ cells/kg. Patients to whom plerixafor was administered late (≥ 15 days) after chemotherapy, after a long duration (≥ 13 days) of treatment with G-CSF, or when the white blood cell count was high (≥ 20 × 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was shown to rescue mobilizations at a comparable rate in patients with critically low levels of peripheral blood CD34+ cells (<3/µL) and those with higher concentrations. These data suggest that late administration of plerixafor in the course of chemotherapy-based mobilization does not contribute to the failure of this strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663509     DOI: 10.3109/10428194.2011.578312

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

2.  Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.

Authors:  L Farina; A Guidetti; F Spina; L Roncari; P Longoni; F Ravagnani; C Carlo-Stella; P Corradini
Journal:  Bone Marrow Transplant       Date:  2013-12-09       Impact factor: 5.483

3.  Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies.

Authors:  Anna Szmigielska-Kaplon; Anna Krawczynska; Magdalena Czemerska; Agnieszka Pluta; Barbara Cebula-Obrzut; Katarzyna Szmigielska; Konrad Stępka; Piotr Smolewski; Tadeusz Robak; Agnieszka Wierzbowska
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

4.  An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.

Authors:  B M Haverkos; A McBride; L O'Donnell; D Scholl; B Whittaker; S Vasu; S Penza; L A Andritsos; S M Devine; S M Jaglowski
Journal:  Bone Marrow Transplant       Date:  2014-05-05       Impact factor: 5.483

Review 5.  Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

6.  Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.

Authors:  Ignacio García-Escobar; Lucía Parrilla; Laura Montejano Ortega; Daniel Castellanos; María Ángeles Montalbán Pallarés; Hernán Cortés-Funés
Journal:  Mol Clin Oncol       Date:  2014-07-29

7.  Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

Authors:  C T Kouroukis; N P Varela; C Bredeson; J Kuruvilla; A Xenocostas
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

8.  Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Authors:  M E Horwitz; J P Chute; C Gasparetto; G D Long; C McDonald; A Morris; D A Rizzieri; K M Sullivan; N J Chao
Journal:  Bone Marrow Transplant       Date:  2011-11-14       Impact factor: 5.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.